Arteris (AIP) Q3 2026 Earnings Call Transcript

Arteris reported Q3 2026 revenue of $25.8 million, up 48% year over year and above guidance, while ACV plus royalties rose 39% to about $104 million and RPO reached a record $135 million. The company raised full-year revenue guidance by $2.5 million to $98.5 million-$99.5 million and improved its non-GAAP operating loss outlook by $300,000; full-year free cash flow guidance remains $5 million-$9 million. Management cited AI and chiplet demand, with chiplets representing about 10% of designs today and projected to reach 30%-35% over the next two to three years; quarterly free cash flow was negative $2.1 million.

Analysis

AIP: design wins are the asset; conversion is the test. In this IP model, design starts can lead royalties only after customers ship silicon, so the near-term gap between strong contracted indicators and relatively steady quarterly revenue is a timing risk—not yet proof of monetization at the rate implied by the chiplet opportunity. Track royalty growth and RPO conversion, not design-start milestones alone.

The chiplet thesis has attractive operating leverage if each die expands addressable IP and royalty-bearing programs. But management’s “each chiplet is a project” framing is not a one-for-one revenue multiplier: customer discounts, project cancellations, and adoption timing determine realized economics. Arteris can benefit alongside AMD and other designers, while Synopsys and Cadence remain potential competitors or bundling partners; larger IP suites may constrain standalone pricing. A further risk is that customers or ecosystem standards simplify or internalize parts of die-to-die data movement.

Near term, guidance supports execution but does not remove the risk of lumpier license timing. Over 1–3 months, watch Q4 delivery and evidence that ACV/royalty growth converts to revenue and cash. Over 6–18 months, chiplet mix and commercial cybersecurity adoption are the upside levers. The security opportunity is less proven than the core NoC business; government-contract subcontractor costs and RSU-related payroll taxes also make reported operating leverage noisier. Cash reduces financing risk, but the completed ATM means dilution is already part of the capital structure.

Contrarian read: the market may overvalue the count of design starts and underweight the long conversion cycle and negotiated economics. Conversely, a quarter of soft sequential ACV would not alone invalidate the thesis given deal lumpiness. Without current price, valuation, and post-call reaction, avoid asserting mispricing or chasing an earnings gap.

Key Decisions for Investors

• Watch rather than chase: verify AIP’s current valuation and post-earnings move before initiating; consider a staged long only if the price action does not assume chiplet upside is already fully realized.
• For the next 1–3 months, monitor Q4 revenue against guidance, ACV plus royalties, and cash conversion. Reassess the long thesis if the company misses guidance or royalty growth materially decelerates without a timing explanation.
• For a 6–18 month thesis, require evidence that chiplet design activity converts into paid projects and recurring royalties, and that commercial security sales expand beyond government-related work; treat design-start counts as leading indicators, not revenue.
• Potential hedge for a long AIP position: short a semiconductor-sector ETF to reduce broad chip-cycle exposure, subject to checking AIP’s current beta and borrow/carry. The thesis is falsified if chiplet adoption rises but AIP royalty or revenue conversion fails to follow.